Medical Condition

intractable epilepsy

Total Trials

1

Recruiting Now

1

Trial Phases

Various

Epilepsy clinical trials increasingly focus on treatment-resistant epilepsy (TRE) — defined as failure of two adequate antiseizure medication (ASM) trials — where one-third of patients remain uncontrolled. Genetic stratification has driven trials in specific epilepsy syndromes (Dravet, Lennox-Gastaut, SCN1A, KCNQ2) where disease-modifying gene therapy approaches are now being tested.

Active trials investigate fenfluramine for treatment-resistant focal epilepsy, KCNQ2/SCN1A antisense oligonucleotides, sodium selenate for progressive myoclonic epilepsy, novel mTOR inhibitors for TSC-related epilepsy, and responsive neurostimulation (RNS). Seizure frequency and seizure-free rates remain primary endpoints, with ESES and status epilepticus trials gaining traction.

Top Sponsors

University of Michigan 1 trial

NCT07014592

Recruiting

Characterization and Analysis of Evoked Cortical Responses in Participants With Medication-intractable Epilepsy

University of Michigan

View Trial →

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology